Pharmacy news

• Monitor Nutrition and Muscle Loss in Patients on Incretin-Based Obesity Drugs

  22-09-2026 18:31 via pharmacypracticenews.com
  
  By Gina ShawAs much as 40% of the weight patients lose on incretin-based obesity medications can come from lean mass, and roughly 1 in 5 meets the criteria for malnutrition after a year of therapy, cautioned presenters during a Malnutrition Awareness Week 2026 webinar, held by the American Society for Parenteral and Enteral Nutrition.“Incretin-based medications are not the problem. The problem is the lack of nutrition education, guidance, and monitoring,” said Colleen Dawkins, FNP-C,
  
  Read more

• Jideytro Approved for Previously Treated ROS1-Positive NSCLC

  22-09-2026 04:00 via pharmacypracticenews.com
  
  Originally published by our sister publication Clinical Oncology NewsBy Sarah TilyouThe FDA approved zidesamtinib (Jideytro, GlaxoSmithKline) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have received at least one prior ROS1 tyrosine kinase inhibitor (TKI).figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block
  
  Read more

Follow @newsl_pharmacy on Twitter!